Genticel Raises €13.1 Million
Genticel (f.k.a. BT Pharma), a French developer of immunotherapies to prevent cancers caused by HPV, has raised €13.1 million in new VC funding. AGF Private Equity led the round, and was joined by the Institut Régional de Développement Industriel, Amundi Private Equity Funds, InnoBio fund (CDC Enterprises) and return backer Edmond de Rothschild Investment Partners.
10 March 2010•7 mins read
